Sorry, you need to enable JavaScript to visit this website.

DAURISMO™ (glasdegib) Drug Interactions

7 DRUG INTERACTIONS

Table 5. Drug Interactions with DAURISMO
Strong CYP3A Inhibitors
Clinical Impact
Prevention or Management
  • Consider alternative therapies that are not strong CYP3A4 inhibitors during treatment with DAURISMO.
  • Monitor patients for increased risk of adverse reactions including QTc interval prolongation [see Warnings and Precautions (5.2)].
Strong and Moderate CYP3A Inducers
Clinical ImpactCo-administration of DAURISMO with strong and moderate CYP3A inducers decreased glasdegib plasma concentrations [see Clinical Pharmacology (12.3)].
  • Decreased glasdegib concentrations may reduce efficacy.
Prevention or Management
  • Avoid co-administration of DAURISMO with strong and moderate CYP3A4 inducers.
  • If co-administration of DAURISMO with moderate CYP3A4 inducers cannot be avoided, increase the dose of DAURISMO [see Dosage and Administration (2.3)].
QTc Prolonging Drugs
Clinical ImpactCo-administration of DAURISMO with QTc prolonging drugs may increase the risk of QTc interval prolongation [see Warnings and Precautions (5.2)].
Prevention or Management
  • Avoid co-administration of QTc prolonging drugs with DAURISMO or replace with alternative therapies.
  • If co-administration of a QTc prolonging drug is unavoidable, monitor patients for increased risk of QTc interval prolongation [see Warnings and Precautions (5.2)].

What's New

No Current Announcements.

Contact Pfizer Medical

Report an Adverse Event
1-800-438-1985

Search

Please enter your search term(s) for DAURISMO™